IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor

  • Authors:
    • Takemi Otsuki
    • Haruko Sakaguchi
    • Masaaki Eto
    • Tomohiro Fujii
    • Tamayo Hatayama
    • Akiko Takata
    • Takayuki Tsujioka
    • Takashi Sugihara
    • Fuminori Hyodoh
  • View Affiliations

  • Published online on: September 1, 2003     https://doi.org/10.3892/ijo.23.3.763
  • Pages: 763-768
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although recent developments in initial chemotherapeutic regimens and stem cell transplantation have achieved improvements of initial remission for myeloma patients, relapse and recurrence are still major problems. The 3-hydroxy-3-mehtylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been developed for treating hyperlipidemia. Recently, there have been several reports concerning the effects of statins on cancer cells including liver, colon, leukemia, malignant B, stomach, and breast cells. In this study, the in vitro effects of pravastatin on human myeloma cells and the factors closely related to its growth inhibitory effects were examined. Although concentrations were higher than those used clinically, 4 out of 10 myeloma lines showed growth inhibition by pravastatin. The study of factors related to the inhibition indicated IL-6 is important. Indeed, rhIL-6 abolished pravastatin-induced growth inhibition in KMS-21BM cells which did not express IL-6. Statins may be useful in maintenance therapy for myeloma after the screening of IL-6 status.

Related Articles

Journal Cover

September 2003
Volume 23 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Otsuki T, Sakaguchi H, Eto M, Fujii T, Hatayama T, Takata A, Tsujioka T, Sugihara T and Hyodoh F: IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor. Int J Oncol 23: 763-768, 2003.
APA
Otsuki, T., Sakaguchi, H., Eto, M., Fujii, T., Hatayama, T., Takata, A. ... Hyodoh, F. (2003). IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor. International Journal of Oncology, 23, 763-768. https://doi.org/10.3892/ijo.23.3.763
MLA
Otsuki, T., Sakaguchi, H., Eto, M., Fujii, T., Hatayama, T., Takata, A., Tsujioka, T., Sugihara, T., Hyodoh, F."IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor". International Journal of Oncology 23.3 (2003): 763-768.
Chicago
Otsuki, T., Sakaguchi, H., Eto, M., Fujii, T., Hatayama, T., Takata, A., Tsujioka, T., Sugihara, T., Hyodoh, F."IL-6 is a key factor in growth inhibition of human myeloma cells induced by pravastatin, an HMG-CoA reductase inhibitor". International Journal of Oncology 23, no. 3 (2003): 763-768. https://doi.org/10.3892/ijo.23.3.763